AgingResearch.NewsJoin free

TERN-601

Intervention

1 paper2 findings

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Labs are independent when their papers share no last author and no institution.

Against: findings that point the other way from most findings on the same outcome.

On aging: the drug’s trials ARN judged to be about aging, of every trial that tests it for any use.

No results posted: trials that ended more than a year ago with no results on ClinicalTrials.gov and no paper in ARN’s record.

Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.

  • 1 lab
  • Human trial1

Outcomes

2

Weight loss

upin humans1

1 study

  1. TERN-601 induces weight loss in humans (67% achieved ≥5% weight loss).

    “At TERN-601 740 mg, 67% of participants achieved ≥5% weight loss.”

    Human trialin participants with obesity or overweight740 mg28 days

    Effect of Oral Small Molecule GLP-1 Receptor Agonist TERN-601 in Healthy Participants with Obesity or Overweight—A First-in-Human Study

    ADA Scientific Sessions 2025 abstract13 Jun 2025

Body weight

downin humans1−5.5%

1 study

  1. TERN-601 decreases body weight in humans (up to -5.5%).

    “All TERN-601 doses showed continuous mean weight loss (up to -5.5%) over 28 days”

    Human trialin participants with obesity or overweight28 days

    Effect of Oral Small Molecule GLP-1 Receptor Agonist TERN-601 in Healthy Participants with Obesity or Overweight—A First-in-Human Study

    ADA Scientific Sessions 2025 abstract13 Jun 2025

Latest

Related